-
Mashup Score: 0TPO Receptor Agonist for CAR-T-Associated Persistent Cytopenia - 2 year(s) ago
TPO receptor agonist treatment for severe persistent cytopenia associated with CAR-T therapy resulted in complete cytopenia remission among most patients.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Oncology Nursing News - 2 year(s) ago
homejournalsoncology-nurseOncology Nursing News® is published 6 print issues every year. This page features the content from those publications.June 2022Volume: 16Issue: 3April 2022Volume: 16Issue: 2February 2022Volume: 16Issue: 1December 2021Volume: 15Issue: 6October 2021Volume: 15Issue: 5August 2021Volume: 15Issue: 4June 2021Volume: 15Issue: 3April 2021Volume: 15Issue: 02February 2021Volume:…
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Issue Alert! Check out @OncNursingNews June Issue at https://t.co/PxuzJsDA9C #oncology #nursing #NurseTwitter #CARTtherapy #AACR22 #ONSCongress #kcsm #melnsm #mmsm https://t.co/FPkNba6NsC
-
-
Mashup Score: 0Using lentiviral vectors to generate CAR-T cells - 2 year(s) ago
In this video, Sid P. Kerkar, MD, Exuma Biotech, West Palm Beach, FL, discusses the generation of chimeric antigen receptor…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sid P. Kerkar (@ExumaBiotech) discusses the use of lentiviral vectors to generate CAR-T cells. Watch the full interview here: 🎥: https://t.co/6Lf5ktlNRd @AACR #AACR22 #CARTTherapy #tcellrx #HemOnc #ImmunoOnc
-
-
Mashup Score: 0
Saurabh Dahiya, MD, University of Maryland School of Medicine, Baltimore, MD, shares the results of a study investigating immunogenicity to…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Tandem22 | Saurabh Dahiya (@UMmedschool) discusses COVID-19 vaccination in patients with B-cell malignancies following CAR-T therapy. 🎥 Watch now: 👉https://t.co/xmQMG34Cxa👈 @ASTCT @CIBMTR #BMTsm #HemOnc #LymSM #CARTTherapy #tcellrx #ImmunoOnc
-
-
Mashup Score: 2mRNA delivery for the development of T cell therapies: the potential of polydopamine nanosensitizers - 2 year(s) ago
Dominika Berdecka, University of Ghent, Ghent, Belgium, provides an overview of a study presented at the International Conference on Lymphocyte…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
mRNA delivery for the development of T cell therapies: the potential of polydopamine nanosensitizers | Dominika Berdecka (@ugent) shares some insights: 👉https://t.co/x5d7esqrrh👈 @ICLE_lymphocyte #ICLE22 #CARTTherapy #tcellrx
-
-
Mashup Score: 2CAR-T therapy in pediatric and adult ALL - 2 year(s) ago
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel talks on the current status of chimeric antigen receptor T-cell (CAR-T)…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Arnon Nagler (@nagler_EBMT) shares some insights on CAR-T therapy in pediatric and adult ALL.💉 Watch now: 👉https://t.co/CyhMjZ0b0s👈 @TheEBMT #EBMT22 #HemOnc #ALLsm #LeuSM #CARTTherapy #tcellrx #ImmunoOnc
-
-
Mashup Score: 0
Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, gives an overview of targeting neoantigens in patients with multiple…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Angela Krackhard (@TU_Muenchen) spoke with us at #ICLE22 on generating neoantigen-specific CAR-T therapies for MM. Watch now: 👉https://t.co/DXN4PV6Jfu👈 @ICLE_lymphocyte #HemOnc #MMsm #Myeloma #CARTTherapy #tcellrx #ImmunoOnc
-
-
Mashup Score: 10The future of CAR-T therapy for multiple myeloma - 2 year(s) ago
Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, talks on the development of CAR T-cell therapy…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CAR-T cells are changing the myeloma treatment landscape. Niels van de Donk, MD, PhD, shares some interesting insights: 👉https://t.co/nJsFzUDN8K👈 @ASH_hematology #ASH21 #MMsm #MyelomaAwarenessMonth #MYelomaAction #Myeloma #HemOnc #CARTcells #CARTTherapy #tcellrx https://t.co/Ykv2NyPCxp
-
-
Mashup Score: 0The efficacy of a third dose of the COVID-19 vaccine in HCT, CAR-T and BiTE recipients - 2 year(s) ago
In this video, Muhammad Bilal Abid, MD, MRCP, Medical College of Wisconsin, Milwaukee, MI, discusses the results from a study…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Muhammad Bilal Abid of @MedicalCollege discusses the efficacy of a third dose of the COVID-19 vaccine in HCT, CAR-T and BiTE recipients: 👉https://t.co/uUlzlfUbRu👈 #CARTcell #tcellrx #Lymphoma #LymSM #Myeloma #MMsm #CARTtherapy
-
-
Mashup Score: 1Setting up and running a CAR-T unit: patient’s perspective - 2 year(s) ago
Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, shares some information on her presentation at the EBMT-EHA 4th European CAR T-cell…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Setting up and running a CAR-T unit: patient's perspective | @LornaWarwick of @knowyournodes shares some insights. Watch her interview now: 👉https://t.co/GkqVLlz3xq👈 @TheEBMT @EHA_Hematology #CART22 #CARTtherapy #ImmunoOnc #HemOnc #CART #tcellrx #Lymphoma #LymSM
-
TPO receptor agonist treatment for severe persistent #cytopenia associated with anti-CD-19 chimeric antigen receptor T therapy resulted in complete cytopenia remission among most patients. https://t.co/ljkv18Sin8 #CARTTherapy